Neurology
Alzheimer’s Pill Has Finished the Trial. Evidence Has Not.
AriBio’s POLARIS-AD Phase III trial of AR1001 has completed its 52-week treatment phase. The safety update is useful, but the result that matters is still coming.
When Dementia Takes Speech, Trials Must Catch Up
Child Mental Health Access Still Depends on the Facility
Huntington’s Gets Another Chance at Proof
Duchenne Evidence Moves Into the Muscle
Migraine Prevention Gets a Wider Door
Stroke Rehab Cannot Stop at Survival
Alzheimer’s Trials Are Finally Blood-Gated
MS Regulators Are No Longer Reading the Same Risk
Europe Opens the SMA Gene-Therapy Door Wider
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.